BIOCYTOGEN PHARMA. H YC1 Tangible Net Worth Ratio
BIOCYTOGEN PHARMA. H YC1 tangible net worth ratio. BIOCYTOGEN PHARMA. H YC1 (I54) has a Tangible Net Worth Ratio of 99.4% as of December 2025. This metric is calculated by deducting intangible assets (€13.36 Million) from net assets (€2.18 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See debt-free asset ratio of BIOCYTOGEN PHARMA. H YC1 to measure how much of total assets are equity-financed.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of BIOCYTOGEN PHARMA. H YC1 (2021–2025)
Tangible net worth ratio of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025. This chart shows how BIOCYTOGEN PHARMA. H YC1's Tangible Net Worth Ratio has changed across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 99.4%, reflecting net assets of €2.18 Billion with intangible assets of €13.36 Million EUR. See working capital position of BIOCYTOGEN PHARMA. H YC1 to evaluate short-term liquidity relative to the company's equity base.
BIOCYTOGEN PHARMA. H YC1 Tangible Net Worth Ratio by Year (2021–2025)
BIOCYTOGEN PHARMA. H YC1 tangible net worth ratio by year from 2021 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see I54 stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 99.4% | €2.18 Billion | €13.36 Million | €3.72 Billion | ▲ +1.9 pp |
| 2024 | 97.5% | €838.60 Million | €20.66 Million | €2.42 Billion | ▲ +1.1 pp |
| 2023 | 96.4% | €790.44 Million | €28.13 Million | €2.45 Billion | ▼ -0.9 pp |
| 2022 | 97.3% | €1.15 Billion | €30.65 Million | €2.80 Billion | ▼ -2.2 pp |
| 2021 | 99.5% | €1.25 Billion | €6.05 Million | €2.30 Billion | — |